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Abstract
Background: In 2017, approximately 73% of antibiotics in England were prescribed from primary care 
practices. It has been estimated that 9%–23% of antibiotic prescriptions between 2013 and 2015 were 
inappropriate. Reducing antibiotic prescribing in primary care was included as one of the national 
priorities in a financial incentive scheme in 2015–2016.
Aim: To investigate whether the effects of the Quality Premium (QP), which provided performance- 
related financial incentives to clinical commissioning groups (CCGs), could be explained by practice 
characteristics that contribute to variations in antibiotic prescribing.
Design & setting: Longitudinal monthly prescribing data were analysed for 6251 primary care 
practices in England from April 2014 to March 2016.
Method: Linear generalised estimating equations models were fitted, examining the effect of the 
2015–2016 QP on the number of antibiotic items per specific therapeutic group age–sex related 
prescribing unit (STAR- PU) prescribed, adjusting for seasonality and months since implementation. 
Consistency of effects after further adjustment for variations in practice characteristics were also 
examined, including practice workforce, comorbidities prevalence, prescribing rates of non- antibiotic 
drugs, and deprivation.
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Results: Antibiotics prescribed in primary care practices in England reduced by -0.172 items per 
STAR- PU (95% confidence interval [CI] = -0.180 to -0.171) after 2015–2016 QP implementation, with 
slight increases in the months following April 2015 (+0.014 items per STAR- PU; 95% CI = +0.013 to 
+0.014). Adjusting the model for practice characteristics, the immediate and month- on- month effects 
following implementation remained consistent, with slight attenuation in immediate reduction from 
-0.172 to -0.166 items per STAR- PU. In subgroup analysis, the QP effect was significantly greater 
among the top 20% prescribing practices (interaction p<0.001). Practices with low workforce and 
those with higher diabetes prevalence had greater reductions in prescribing following 2015–2016 QP 
compared with other practices (interaction p<0.001).
Conclusion: In high- prescribing practices, those with low workforce and high diabetes prevalence had 
more reduction following the QP compared with other practices, highlighting the need for targeted 
support of these practices and appropriate resourcing of primary care.
How this fits in
The QP has previously been associated with reductions in antibiotic prescribing in primary care 
practices in England. To the authors’ knowledge, this study is the first to investigate the other possible 
explanations of the effect of the QP on antibiotic prescribing in primary care practices, strengthening 
the evidence on the effectiveness of this financial incentive scheme. The results show a consistent 
effect of QP after accounting for differences in practice characteristics, indicating its inclusiveness 
in reaching diverse populations. The study provides novel evidence on the differential effect of QP, 
emphasising the role of CCGs in identifying and supporting higher- prescribing practices, understaffed 
practices, and those dealing with a high prevalence of comorbidities.
Introduction
The overuse of antibiotics drives resistance through the selection of antibiotic- resistant strains of 
organisms.1–3 Primary care is the main contributor to antibiotic usage in England, constituting 
approximately 73% of antibiotics prescribed in 2017.4 It is estimated that 9%–23% of antibiotic 
prescriptions in primary care practices in England between 2013 and 2015 were inappropriate, which 
is based on prescribing guidelines.5
Antibiotic prescribing is recommended in the management of respiratory tract infections (RTIs) in 
some patients, including older patients with diabetes or heart failure, who are considered at particular 
risk of developing complications.6 The prevalence of comorbidities such as diabetes varies over time 
and geographical area, contributing to the disparities in the antibiotic prescribing pattern within and 
between primary care practices.7,8
Several approaches have been adopted to reduce primary care antibiotic prescribing in England 
including: increased surveillance and prescribing feedback; the provision of C- reactive protein point- 
of- care testing; education and training interventions targeted at prescribers and patients; public 
antimicrobial stewardship (AMS) campaigns; and financial incentives.9,10 The QP is an NHS England 
performance- related incentive scheme established in 2013 to reward CCGs financially, based on the 
quality of specific health services considered to be national or local priorities and commissioned over 
a specific period.9 Individual GP practices did not receive financial remuneration in relation to this 
award. Reducing antibiotic prescribing in primary care was included as one of the national priorities in 
the 2015–2016 QP guidance, targeting a reduction of 1% of the mean value in England in 2013–2014 
(1.161 antibiotic items per STAR- PU) for a CCG to obtain the financial incentive (provided other non- 
antibiotic targets, such as early cancer diagnosis, improving GP access and experience, continuing 
health care, and mental health, were also met).
The QP intervention has been associated with substantial reductions in antibiotic prescribing in 
primary care practices in England,4,11–13 specifically a reduction of about 2.7 million antibiotic items 
between 2014–2015 and 2016–2017 financial years (1 April to 31 March).4 Such reductions in antibiotic 
prescribing would be expected to contribute to reductions in the development of resistance.14
However, it is not clear whether these reported reductions can be entirely attributed to the QP as 
current evaluations have not accounted for other possible explanations, such as variations in practice 
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characteristics over time. The main aim of this study was, therefore, to investigate whether differences 
in primary care practice characteristics, which can contribute to variance in antibiotic prescribing 
(practice workforce, the prevalence of comorbidities, prescribing rate on non- antibiotic drugs, and 
deprivation index), explained any of the effects of the QP scheme on the prescribing rates in primary 
care practices. Furthermore, the study investigated whether the QP had a differential effect on high- 
prescribing practices and other subgroups of practices.
Method
Study design
New QP guidance was implemented at the start of each financial year in England with changes in 
the targeted reductions in antibiotic prescribing and its associated award. This study adopted a 
natural experiment approach in investigating the mechanism of impact of the 2015–2016 QP target 
on antibiotic prescribing in primary care practices in England, with the preceding financial year as 
the control, by conducting analyses of longitudinal (monthly) prescribing data for 6251 primary care 
practices in England from April 2014 to March 2016. While there are more recent antibiotic prescribing 
data, including data beyond March 2016would have meant exceeding the period covered by the 
2015–2016 QP guidance, as prescribing in subsequent periods are covered by different QP guidance 
and targets.
Like antibiotics, the prescription of opioids and benzodiazepines is monitored in the UK with 
prescribers encouraged to reduce their prescription.15 The frequency of prescribing of these drugs has 
been reported as an indicator of antibiotic prescribing rates.16 Adjusting for the prescribing behaviour 
of opioids and benzodiazepines was important to account for the overall medicine prescribing 
behaviour of practices that might not be specific to antibiotics.
Variables
Outcome
The primary outcome was a continuous variable indicating the number of antibiotic items per STAR- 
PU prescribed by a practice in England per month. Practice- level antibiotic prescribing data were 
sourced from OpenPrescribing (an Evidence- Based Medicine DataLab project at the University of 
Oxford) and STAR- PU weighted using figures from the 2013 item- based age–sex weighting for oral 
antibacterials,17 and the number of registered patients in each age–sex category in a practice for each 
specific month.18
Predictors
The main predictor was a binary variable indicating the implementation of the 2015–2016 QP. The 
intervention period included April 2015 to March 2016 with the control period as the prior 12 months 
(that is, April 2014 to March 2015). A continuous variable representing the number of months since 
2015–2016 QP implementation was used to examine changes in trend in the months following the 
intervention.
confounder and effect modifiers
Confounder and effect modifiers in this study included:
•	 the number of GPs per 10 000 patients in each practice for each financial year (sourced from the 
NHS workforce data);19
•	 the Index of Multiple Deprivation (IMD), computed based on the lower super output area for 
each practice's postcode20,21 (this only accounts for the site of practice and not patient- level 
data);
•	 yearly prevalence of specific comorbidities per 100 patients, namely asthma, chronic obstruc-
tive pulmonary disease (COPD), diabetes mellitus (for type 1 and 2), cancer, and chronic kidney 
disease, from the NHS Quality and Outcomes Framework (QOF) database (QOF data do not 
distinguish between type 1 and type 2 diabetes mellitus).22 These comorbidities have been 
chosen as their prevalence is relevant to the antibiotic prescribing rate of a practice given that 
antibiotic prescribing is recommended in the management of some patients with RTI with these 
Anyanwu PE et al. BJGP Open 2020; DOI: 10.3399/bjgpopen20X101052
 
 4 of 12
Research
comorbidities;6,23–25 and,
•	 the monthly prescribing rate of opioids and benzodiazepines (per 100 patients) from practice 
level prescribing data published by NHS Digital.26
Data from the different sources were linked using practice code, which is a unique identifier for 
practices in England. Data from OpenPrescribing and NHS Digital are from the same source: NHS 
Business Services Authority prescribing and dispensing information systems.
As the analysis is at a monthly level, all models were adjusted for seasonality (using a categorical 
term with winter as the reference category) to account for the seasonal differences in antibiotic 
prescribing, with increased incidence of RTIs during the winter months associated with higher 
antibiotic prescribing.27
The dataset covered 7549 practices existing over the study period. 876 practices were dropped 
due to incomplete observation for all variables (11.6%; mostly practices that closed or opened during 
the study period) and then 422 practices (5.6%) that were outliers were dropped using the interquartile 
range rule; therefore, the final analyses included 6251 (82.8%) practices.
Statistical analysis
Generalised estimating equations models were fitted with an autoregressive ‘AR(1)’ covariance 
structure28 to investigate the effect of the 2015–2016 QP on antibiotic prescribing. The first model 
included variables reflecting the 2015–2016 QP and the number of months since its implementation 
as the predictors, adjusting for seasonality.
To examine whether this estimated effect of the 2015–2016 QP on antibiotic prescribing was 
explained by differences in practice characteristics that can contribute to variance in antibiotic 
prescribing, variables were intoduced reflecting practice characteristics (workforce size, prevalence of 
comorbidities, rate of prescribing of non- antibiotic drugs, and IMD) to investigate whether the effect 
of the QP was retained, declined, or intensified.
Table 1 Characteristics of general practices, N = 6251
Mean, entire study 
population,
2014–2015 &  
2015–2016,
% (95% CI)
Mean, period 
before QP,
2014–2015,
% (95% CI)
Mean, period 
after QP,
2015–2016,
% (95% CI)
Mean, top 20% of pre-
scribing practices,
2014–2015 & 
2015–2016,
% (95% CI)
Antibiotic items per STAR- PU 1.057
(1.055 to 1.059)
1.106
(1.103 to 1.108)
1.009
(1.007 to 1.011)
1.357
(1.354 to 1.360)
Asthma prevalence
per 100 patients
5.941
(5.935 to 5.947)
5.980
(5.971 to 5.989)
5.901
(5.893 to 5.911)
6.295
(6.281 to 6.309)
COPD prevalence
per 100 patients
1.878
(1.873 to 1.882)
1.861
(1.855 to 1.867)
1.894
(1.888 to 1.900)
2.301
(2.291 to 2.312)
Cancer prevalence
per 100 patients
2.346
(2.342 to 2.350)
2.264
(2.258 to 2.270)
2.428
(2.421 to 2.434)
2.230
(2.291 to 2.309)
CKD prevalence
per 100 patients
4.129
(4.119 to 4.139)
4.143
(4.129 to 4.157)
4.115
(4.101 to 4.129)
4.420
(4.398 to 4.442)
Diabetes prevalence
per 100 patients
6.635
(6.626 to 6.645)
6.544
(6.532 to 6.557)
6.726
(6.713 to 6.740)
7.316
(7.298 to 7.335)
Opioids prescription
per 100 patients
3.273
(3.265 to 3.282)
3.241
(3.229 to 3.253)
3.306
(3.293 to 3.318)
4.306
(4.285 to 4.328)
Benzodiazepine
anxiolytics prescription
per 100 patients
0.917
(0.914 to 0.919)
0.920
(0.916 to 0.924)
0.913
(0.910 to 0.917)
1.151
(1.145 to 1.158)
Benzodiazepine
hypnotics prescription
per 100 patients
1.311
(1.308 to 1.315)
1.333
(1.328 to 1.338)
1.289
(1.284 to 1.294)
1.673
(1.664 to 1.682)
GP workforce
per 10 000 patients
6.126
(6.112 to 6.139)
6.429
(6.412 to 6.446)
5.822
(5.802 to 5.842)
5.835
(5.805 to 5.864)
CKD = chronic kidney disease. COPD = chronc obstructive pulmonary disease. QP = Quality Premium. STAR- PU = specific therapeutic 
group age–sex related prescribing unit.
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In the multivariable model, variables causing multicollinearity were excluded (defined by opposite 
effects in univariable and multivariable models and high Spearman correlation >0.5). To address 
non- linearity, the association was modelled between the outcome and workforce using linear spline 
terms with knots equally spaced over the range of the workforce data (at 4.91, 9.81, and 14.72). 
A principal component analysis (PCA) was used to compute a summary score reflecting respiratory 
diseases comorbidity (using asthma and COPD prevalence). The PCA produced two components 
with eigenvalues of 1.41 and 0.59. The first component was retained (with an eigenvalue >1), which 
explained 71% of the variation in the data on respiratory diseases prevalence.
Subgroup analyses were also conducted using interaction terms to examine whether the 2015–
2016 QP had a differential effect on antibiotic prescribing among: high- prescribing practices (the top 
20% prescribing practices based on the mean antibiotic items per STAR- PU prescribed in 2014–2015); 
practices with a higher prevalence of comorbidities; low workforce; and in deprived areas. For more 
detailed analysis of the differential effect of QP based on levels of comorbidity prevalence, the study 
used linear spline functions with knots equally spaced over the range of the variables on diabetes 
prevalence (knots at 3.93, 7.60, and 11.28) and the PCA summary score for respiratory diseases (knots 
at -2.05, 0.32, and 2.70).
All analyses were conducted using Stata (version 15.1). Results for all models are presented as 
coefficients with 95% CIs.
Results
The data constituted 150 024 observations for 6251 practices; each practice contributed data for 
24 months. The mean number of antibiotic items prescribed in 2014–2015 QP was 1.106 items per 
STAR- PU (95% CI = 1.103 to 1.108); this was 0.097 items higher than the mean in the post- intervention 
period (Table 1). The top 20% prescribing practices had fewer GPs per 10 000 patients, higher rates of 
prescriptions for the non- antibiotic drugs, and higher prevalence of comorbidities (apart from cancer) 
compared with the entire population.
Table 2 Association between QP and antibiotic prescribing, N = 6251
Model without adjustment for 
practice characteristics
Model with adjustment for
practice characteristics
Co- efficient
95% CI
Co- efficient
95% CI
Lower Upper Lower Upper
2015–2016 QP -0.172 -0.176 -0.168 -0.166 -0.170 -0.162
Months since QP 0.014 0.013 0.014 0.014 0.013 0.014
Season Winter Ref Ref Ref Ref Ref Ref
Spring -0.040 -0.043 -0.038 -0.044 -0.046 -0.041
Summer -0.153 -0.156 -0.150 -0.139 -0.142 -0.136
Autumn -0.132 -0.135 -0.129 -0.119 -0.121 -0.116
Comorbidities Respiratory disease – – – 0.021 0.018 0.024
Diabetes prevalence – – – 0.028 0.026 0.030
Benzodiazepine anxiolytics prescription – – – 0.123 0.118 0.127
Benzodiazepine hypnotics prescription – – – 0.160 0.157 0.164
GPHC per 10 000 
patients
(spline terms)
GPHC1 (<4.91) – – – 0.013 0.011 0.015
GPHC2 (≥4.91 to 
≤9.80)
– – – -0.008 -0.010 -0.006
GPHC3 (≥9.81 to 
≤14.72)
– – – 0.07 0.002 0.011
GPHC4 (>14.72) – – – -0.006 -0.021 0.008
Effects of GPHC are per one increase in GP number per 10 000 patients within each spline term. GPHC = GP 
headcount. QP = Quality Premium.
Anyanwu PE et al. BJGP Open 2020; DOI: 10.3399/bjgpopen20X101052
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Univariable models showed the predictors and covariates (apart from the last spline term for 
workforce) were all significantly associated with the antibiotic prescribing rate in primary care practices 
in England (see Supplementary Table S1).
Effect of the 2015–2016 QP on antibiotic prescribing (adjusting for 
seasonality)
Antibiotic prescribing in general practices in England reduced by -0.172 items per STAR- PU (95% CI 
= -0.176 to -0.168) after 2015–2016 QP implementation in April 2015 compared with the 12 months 
before (Table 2 and Figure 1). There was a slight increase in the months following April 2015 (month- 
on- month increase +0.014 items per STAR- PU; 95% CI = +0.013 to +0.014).
Effect of 2015–2016 QP on antibiotic prescribing (further adjusting for 
practice characteristics)
After extending the model to adjust for practice characteristics (comorbidities [respiratory diseases 
and diabetes], prescribing rate of benzodiazepine, and GP workforce), the immediate and month- 
on- month effects seen after 2015–2016 QP implementation remained consistent, with only a slight 
attenuation in mean reduction in items prescribed immediately following the QP from -0.172 to -0.166 
items per STAR- PU, a 3.5% relative reduction in effect size (Table 2).
Subgroup analysis
With the subgroup analyses, the study examined whether the effect of the QP on antibiotic prescribing 
was greater within specific subgroups of practices, such as those that are among the top 20% 
prescribers, with a more complex patient population in relation to the prevalence of comorbidities, 
size of workforce, and deprivation index using interaction terms.
The study found a differential effect of the QP among the top 20% prescribers in 2014–2015. The 
reduction in antibiotic prescribing following the QP implementation was greater among the top 20% 
prescribers (-0.200 items per STAR- PU; 35.2% reduction from the rate before QP) compared with 
other practices (-0.116 items per STAR- PU; interaction p<0.001) (Table 3).
For the interaction between QP and diabetes prevalence, a significant variation in prescribing 
behaviour before versus after QP was seen only in practices with diabetes prevalence of between 
Figure 1 Effect of QP on antibiotic prescribing. The shaded portion around the line represents the 95% CI. The vertical line indicates implementation of 
the 2015–2016 QP in April 2015. STAR- PU = specific therapeutic group age–sex related prescribing unit
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7.60% and 11.28% (Figure 2). Before the QP, a 1% higher diabetes prevalence in these practices 
was associated with +0.016 items per STAR- PU greater prescribing (95% CI = +0.012 to +0.021). 
This changed to +0.007 items per STAR- PU (95% CI = +0.002 to +0.011) per 1% higher diabetes 
prevalence after the QP (interaction p<0.001).
The study also found a significant interaction in practices where GP headcount was fewer than 
4.91 and those between 4.91 and 9.81 per 10 000 patients. Following the implementation of QP, the 
understaffed practices (with fewer than 4.91 GPs per 10 000 patients) experienced a decrease in the 
pre- QP increasing trend in antibiotic prescribing (difference -0.008 items per STAR- PU per increase; 
95% CI = -0.010 to -0.005) (interaction p<0.001) (Figure 3). This was different among practices with 
between 4.91 and 9.81 GPs per 10 000 patients where the pre- QP reduction associated with a higher 
GP workforce slightly attenuated. The study found no evidence of significant interaction between QP 
and other spline terms for workforce (interaction p>0.23).
The reduction in antibiotic prescribing after the implementation of the QP was similar for all 
subgroups of practices based on deprivation (interaction p>0.13) or respiratory diseases prevalence 
(interaction p>0.29 for all spline terms).
Discussion
Summary
Table 3 Subgroup analysis
Co- efficient
95% CI
Lower Upper
2015–2016 QP in bottom 80% of prescribers -0.116 -0.125 -0.106
Effect of 2015–2016 QP in top 20% of prescribers -0.200 -0.210 -0.187
Top 20% of prescribers 0.309 0.302 0.316
Months since QP 0.013 0.013 0.014
Season Winter Ref Ref Ref
Spring -0.046 -0.049 -0.044
Summer -0.148 -0.151 -0.145
Autumn -0.124 -0.126 -0.121
Comorbidities
prevalence per 100 
patients
Respiratory diseases 0.013 0.011 0.015
Diabetes (<3.93%) 0.097 0.089 0.106
Diabetes (≥3.93% to ≤7.59%) 0.015 0.012 0.017
Diabetes (≥7.60% to ≤11.28%) before QP 0.016 0.012 0.021
Diabetes (≥7.60% to ≤11.28%) after QP 0.007 0.002 0.011
Diabetes (>11.28%) 0.041 0.030 0.052
GPHC per 10 000 
patients,
spline terms
GPHC1 (<4.91) before QP 0.015 0.013 0.017
GPHC1 (<4.91) after QP 0.007 0.005 0.009
GPHC2 (≥4.91 to ≤9.80) before QP -0.007 -0.009 -0.005
GPHC2 (≥4.91 to ≤9.80) after QP -0.005 -0.007 -0.003
GPHC3 (≥9.81 to ≤14.72) 0.005 -0.000 0.010
GPHC4 (>14.72) -0.007 -0.022 0.008
Benzodiazepine anxiolytics prescription 0.093 0.089 0.097
Benzodiazepine hypnotics prescription 0.118 0.115 0.121
Effects of diabetes are per 1% higher within each spline term. Effects of GPHC are per 1 higher per 10 000 
patients within each spline term. GPHC = GP headcount. QP = Quality Premium.
Anyanwu PE et al. BJGP Open 2020; DOI: 10.3399/bjgpopen20X101052
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Using a longitudinal dataset covering 24 months, the study found that variations in practice 
characteristics did not strongly affect estimates of the impact of the 2015–2016 QP on antibiotic 
prescribing in primary care practices in England. The consistency of the immediate and month- on- 
month effects after accounting for differences in practice characteristics indicates the inclusiveness of 
the QP in reaching diverse populations. Although consistent in both models, the gradual month- on- 
month increase after the dip in prescribing at the implementation of the intervention indicates issues 
of sustainability.
The study also found a differential effect of the 2015–2016 QP on subgroups of practices with a 
significantly greater reduction seen among high- prescribing practices, understaffed practices, and 
Figure 2 Association between diabetes prevalence and antibiotic prescribing before and after the 2015–2016 QP (for diabetes prevalence spline terms). 
The shaded portion around the line represents the 95% CI. QP = Quality Premium
Figure 3 Association between GP workforce and antibiotic prescribing before and after the 2015–2016 QP (for workforce spline terms). The shaded 
portion around the line represents the 95% CI. QP = Quality Premium
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those with a higher prevalence of comorbidities. The greater reduction among high- prescribing 
practices might be explained by the targeted implementation of the QP by CCGs on these practices 
who have more need to reduce prescribing (QP is implemented at CCG level although the outcome 
is measured at practice level). The reduction reported in practices with higher diabetes prevalence 
indicates their ability to work towards reducing prescribing rate, while coping with other needs arising 
from the complexity of their patient population. This finding is important considering the increasing 
trend in diabetes prevalence in the UK,29 and the higher antibiotic prescribing in patients with diabetes 
owing to higher susceptibility to infection and infection- related adverse outcomes.25,30,31
Strengths and limitations
To the authors’ knowledge, the study is the first to account for other possible explanations of the effect 
of the QP on antibiotic prescribing in primary care practices (practice workforce size, prevalence of 
comorbidities, prescribing rate of non- antibiotic drugs, and deprivation), strengthening the evidence 
on the effectiveness of this financial incentive scheme. A large dataset was used including most 
(82.8%) practices in England over the observation period, with 12 months observations before as well 
as after the implementation to capture the temporal trend in antibiotic prescribing.
One of the limitations of the study is that some practice characteristics that could be associated 
with antibiotic prescribing behaviours, such as consultation rates32 and severity of illness, have not 
been accounted for in the analyses as these data are not available nationally at practice level.
Also, it is recognised that the QP is not the only antibiotic stewardship intervention in England in 
the period covered by this study;33 this limits the causal interpretation of the observed effect of the 
2015–2016 QP. However, the QP is the most relevant difference in antibiotic stewardship between 
2014–2015 and 2015–2016 financial years, as most of the national interventions, such as the TARGET 
toolkit (introduced in 2012),34–36 and the chief medical officer’s letter to high prescribers (introduced in 
2014),37 were implemented in both periods.
Comparison with existing literature
Financial incentives have been used to improve performance and quality of care in different clinical 
areas and settings.11,12,38–42 Evaluation studies have reported mixed effects from such incentive 
schemes. While the finding on the immediate effect of the 2015–2016 QP on antibiotic prescribing 
confirms those of other UK studies on this incentive scheme,11,12 some studies have shown a limited 
effect of similar schemes as seen in the month- on- month increase post- QP reported in the study. A 
study in the Netherlands showed a limited, temporary effect of a one- off behaviour independent 
financial bonus on the volume of drug prescriptions and the quality of prescribing behaviour in 
general practice.40 Similar results were reported in a UK study that demonstrated reduction in some 
measures of quality of care following the removal of a financial incentive scheme to improve clinical 
performance.43 However, unlike the QOF evaluated in the study by Minchin et al.,43 QP is paid at CCG 
level only (individual GP practices did not receive financial bonuses based on performance), and CCGs 
need to meet other core criteria to receive the reward.
Furthermore, evaluations of other antibiotic stewardship interventions on high prescribers have 
also shown mixed effects. A behaviour change intervention that provided social norm feedback to 
high- prescribing primary care practices in England on their prescribing behaviour showed an overall 
significant impact in reducing antibiotic prescribing.37 However, a similar randomised clinical trial in 
Switzerland demonstrated that personalised prescription feedback to physicians to reduce antibiotic 
prescribing in primary care made no significant difference in overall antibiotic prescribing.44 These 
studies have mostly focused on interventions that are specifically designed to target high prescribers 
alone.
Implications for research and practice
The study provides novel evidence on the differential effect of the 2015–2016 QP. Highlighting 
the ability of high- prescribing practices, understaffed practices, and those dealing with a higher 
prevalence of comorbidities to make substantial improvements when adequately supported; this 
study emphasises the role of CCGs in identifying and working with these practices.
The substantial scope for change in high- antibiotic prescribing practices illustrated by this study 
should prompt these practices to take action on this issue, and to actively seek support from CCGs 
Anyanwu PE et al. BJGP Open 2020; DOI: 10.3399/bjgpopen20X101052
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in addressing overprescribing. Also, policymakers and antibiotic stewardship programmes should 
target these practices specifically in the design and targeted implementation of antibiotic stewardship 
interventions. The shortage of GPs in NHS primary care is of increasing concern, and the greater effect 
on understaffed practices underlines the need for appropriate resourcing. The current government’s 
promises regarding increased GP numbers notwithstanding,45 CCGs have an important responsibility 
to identify and work with understaffed practices in the implementation of antimicrobial stewardship 
interventions to facilitate performance improvements.
The gradual increase in antibiotic prescribing in the months following the 2015–2016 QP (countering 
some of the immediate effects of the intervention) demonstrates the need for more efforts towards the 
sustainability of the effects of AMS interventions. Approaches to maintain or improve the immediate 
effects of such interventions should be considered at the design stage.
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